fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 28. More products

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Hydromorph Contin (02125382), Hydromorph Contin (02125390). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Hydromorphone HCL

Form:

24 of 24 products shown

22 general benefit · 2 not a benefit

PMS-HYDROmorphone · DIN 01916386 · 1 mg/mL · Oral Sol

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PMS-HYDROmorphone · DIN 01916386 Manufacturer: Pharmascience Inc.; listing date 2006-01-24 Health Canada: Marketed since 1991-12-31 · brand PMS HYDROMORPHONE SIROP 1MG/ML · ATC N02AA03 HYDROMORPHONE · form Syrup · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG/ML · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-HYDROmorphone: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01916386)

Source record
DIN 01916386: PMS-HYDROmorphone Raw flags: sec3=Y Item: 280808013; group id 406; item number 0975; lccId None; manufacturer id PMS Source form: Oral Sol; strength: 1mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916386 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11870
Interchangeable products
Dilaudid · DIN 00786535 · not recorded
Shortage status: resolved shortage (ended December 6, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916386
Shortage record checked October 6, 2026

Apo-Hydromorphone · DIN 02364115 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Hydromorphone · DIN 02364115 Manufacturer: Apotex Inc.; listing date 2012-06-26 Health Canada: Marketed since 2012-12-18 · brand APO-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG · company Apotex inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Hydromorphone: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0959). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364115)

Source record
DIN 02364115: Apo-Hydromorphone Raw flags: sec3=Y Item: 280808017; group id 406; item number 0976; lccId None; manufacturer id APX Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.0959; ministry $0.0959 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364115 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84905
Interchangeable products
Dilaudid · DIN 00705438 · $0.0959 PMS-HYDROmorphone · DIN 00885444 · $0.0959 Teva-Hydromorphone · DIN 02319403 · $0.0959
Shortage status: resolved shortage (ended September 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364115
Shortage record checked October 6, 2026

Dilaudid · DIN 00705438 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Dilaudid · DIN 00705438 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 2008-12-12 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00705438)

Source record
DIN 00705438: Dilaudid Raw flags: sec3=Y Item: 280808017; group id 406; item number 0976; lccId None; manufacturer id PFP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.1061; ministry $0.0959 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00705438 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6889
Interchangeable products
Apo-Hydromorphone · DIN 02364115 · $0.0959 PMS-HYDROmorphone · DIN 00885444 · $0.0959 Teva-Hydromorphone · DIN 02319403 · $0.0959
Shortage status: active shortage (reported September 29, 2026, estimated to end October 12, 2026, last updated September 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00705438
Shortage record checked October 6, 2026

PMS-HYDROmorphone · DIN 00885444 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-HYDROmorphone · DIN 00885444 Manufacturer: Pharmascience Inc.; listing date 2001-10-11 Health Canada: Marketed since 1991-12-31 · brand PMS-HYDROMORPHONE TAB 1MG · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-HYDROmorphone: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0959). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00885444)

Source record
DIN 00885444: PMS-HYDROmorphone Raw flags: sec3=Y Item: 280808017; group id 406; item number 0976; lccId None; manufacturer id PMS Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.0959; ministry $0.0959 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00885444 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11413
Interchangeable products
Apo-Hydromorphone · DIN 02364115 · $0.0959 Dilaudid · DIN 00705438 · $0.0959 Teva-Hydromorphone · DIN 02319403 · $0.0959
Shortage status: resolved shortage (ended August 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00885444
Shortage record checked October 6, 2026

Hydromorphone · DIN 02145901 · 2 mg/mL · injection solution-1mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Hydromorphone · DIN 02145901 Manufacturer: Sandoz Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2005-10-08 · brand HYDROMORPHONE HYDROCHLORIDE INJECTION USP · ATC N02AA03 HYDROMORPHONE · form Solution · route Intramuscular, Intravenous, Subcutaneous · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG/ML · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Hydromorphone: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7830). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02145901)

Source record
DIN 02145901: Hydromorphone Raw flags: sec3=Y Item: 280808014; group id 406; item number 0973; lccId None; manufacturer id SDZ Source form: Inj Sol-1mL Pk; strength: 2mg/mL Recorded listing: General benefit Source prices (unrounded): $1.7830; ministry $1.7830 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02145901 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18315
Interchangeable products
Dilaudid · DIN 00627100 · not recorded
Shortage status: resolved shortage (ended January 31, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02145901
Shortage record checked October 6, 2026

Apo-Hydromorphone · DIN 02364123 · 2 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Hydromorphone · DIN 02364123 Manufacturer: Apotex Inc.; listing date 2012-06-26 Health Canada: Marketed since 2012-12-18 · brand APO-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG · company Apotex inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Hydromorphone: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1417). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364123)

Source record
DIN 02364123: Apo-Hydromorphone Raw flags: sec3=Y Item: 280808018; group id 406; item number 0977; lccId None; manufacturer id APX Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.1417; ministry $0.1417 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364123 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84906
Interchangeable products
Dilaudid · DIN 00125083 · $0.1417 PMS-HYDROmorphone · DIN 00885436 · $0.1417 Teva-Hydromorphone · DIN 02319411 · $0.1417
Shortage status: resolved shortage (ended September 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364123
Shortage record checked October 6, 2026

Dilaudid · DIN 00125083 · 2 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Dilaudid · DIN 00125083 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 2009-01-21 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00125083)

Source record
DIN 00125083: Dilaudid Raw flags: sec3=Y Item: 280808018; group id 406; item number 0977; lccId None; manufacturer id PFP Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.1565; ministry $0.1417 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00125083 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5939
Interchangeable products
Apo-Hydromorphone · DIN 02364123 · $0.1417 PMS-HYDROmorphone · DIN 00885436 · $0.1417 Teva-Hydromorphone · DIN 02319411 · $0.1417
Shortage status: active shortage (reported August 10, 2026, estimated to end October 12, 2026, last updated September 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00125083
Shortage record checked October 6, 2026

PMS-HYDROmorphone · DIN 00885436 · 2 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-HYDROmorphone · DIN 00885436 Manufacturer: Pharmascience Inc.; listing date 1997-04-10 Health Canada: Marketed since 1991-12-31 · brand PMS-HYDROMORPHONE TAB 2MG · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-HYDROmorphone: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1417). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00885436)

Source record
DIN 00885436: PMS-HYDROmorphone Raw flags: sec3=Y Item: 280808018; group id 406; item number 0977; lccId None; manufacturer id PMS Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.1417; ministry $0.1417 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00885436 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11428
Interchangeable products
Apo-Hydromorphone · DIN 02364123 · $0.1417 Dilaudid · DIN 00125083 · $0.1417 Teva-Hydromorphone · DIN 02319411 · $0.1417
Shortage status: resolved shortage (ended August 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00885436
Shortage record checked October 6, 2026

Hydromorph Contin · DIN 02125323 · 3 mg · CR capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Hydromorph Contin · DIN 02125323 Manufacturer: Purdue Pharma; listing date 1998-12-31 Health Canada: Marketed since 1995-12-31 · brand HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 3MG · ATC N02AA03 HYDROMORPHONE · form Capsule (sustained-release) · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 3 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Hydromorph Contin: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8080). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02125323)

Source record
DIN 02125323: Hydromorph Contin Raw flags: sec3=Y Item: 280808097; group id 406; item number 0969; lccId None; manufacturer id PFP Source form: CR Cap; strength: 3mg Recorded listing: General benefit Source prices (unrounded): $0.8080; ministry $0.8080 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02125323 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18556
Shortage status: resolved shortage (ended July 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02125323
Shortage record checked October 6, 2026

Apo-Hydromorphone · DIN 02364131 · 4 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Hydromorphone · DIN 02364131 Manufacturer: Apotex Inc.; listing date 2012-06-26 Health Canada: Marketed since 2012-12-18 · brand APO-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 4 MG · company Apotex inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Hydromorphone: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2240). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364131)

Source record
DIN 02364131: Apo-Hydromorphone Raw flags: sec3=Y Item: 280808019; group id 406; item number 0978; lccId None; manufacturer id APX Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.2240; ministry $0.2240 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364131 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84907
Interchangeable products
Dilaudid · DIN 00125121 · $0.2240 PMS-HYDROmorphone · DIN 00885401 · $0.2240 Teva-Hydromorphone · DIN 02319438 · $0.2240
Shortage status: resolved shortage (ended September 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364131
Shortage record checked October 6, 2026

Dilaudid · DIN 00125121 · 4 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Dilaudid · DIN 00125121 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 2008-12-29 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 4 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00125121)

Source record
DIN 00125121: Dilaudid Raw flags: sec3=Y Item: 280808019; group id 406; item number 0978; lccId None; manufacturer id PFP Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.2469; ministry $0.2240 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00125121 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5940
Interchangeable products
Apo-Hydromorphone · DIN 02364131 · $0.2240 PMS-HYDROmorphone · DIN 00885401 · $0.2240 Teva-Hydromorphone · DIN 02319438 · $0.2240
Shortage status: resolved shortage (ended September 1, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00125121
Shortage record checked October 6, 2026

PMS-HYDROmorphone · DIN 00885401 · 4 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-HYDROmorphone · DIN 00885401 Manufacturer: Pharmascience Inc.; listing date 1999-04-15 Health Canada: Marketed since 1991-12-31 · brand PMS-HYDROMORPHONE TAB 4MG · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 4 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-HYDROmorphone: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2240). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00885401)

Source record
DIN 00885401: PMS-HYDROmorphone Raw flags: sec3=Y Item: 280808019; group id 406; item number 0978; lccId None; manufacturer id PMS Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.2240; ministry $0.2240 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00885401 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11425
Interchangeable products
Apo-Hydromorphone · DIN 02364131 · $0.2240 Dilaudid · DIN 00125121 · $0.2240 Teva-Hydromorphone · DIN 02319438 · $0.2240
Shortage status: resolved shortage (ended July 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00885401
Shortage record checked October 6, 2026

Hydromorph Contin · DIN 02359502 · 4.5 mg · CR capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Hydromorph Contin · DIN 02359502 Manufacturer: Purdue Pharma; listing date 2012-01-19 Health Canada: Marketed since 2011-04-14 · brand HYDROMORPH CONTIN · ATC N02AA03 HYDROMORPHONE · form Capsule (sustained-release) · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 4.5 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Hydromorph Contin: Formulary list price $0.97 per unit (the source does not state the unit; exact figure $0.9749). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02359502)

Source record
DIN 02359502: Hydromorph Contin Raw flags: sec3=Y Item: 280808306; group id 406; item number 0967; lccId None; manufacturer id PFP Source form: CR Cap; strength: 4.5mg Recorded listing: General benefit Source prices (unrounded): $0.9749; ministry $0.9749 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02359502 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84452
Shortage status: resolved shortage (ended August 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02359502
Shortage record checked October 6, 2026

Hydromorph Contin · DIN 02125331 · 6 mg · CR capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Hydromorph Contin · DIN 02125331 Manufacturer: Purdue Pharma; listing date 1998-12-31 Health Canada: Marketed since 1995-12-31 · brand HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 6MG · ATC N02AA03 HYDROMORPHONE · form Capsule (sustained-release) · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 6 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Hydromorph Contin: Formulary list price $1.21 per unit (the source does not state the unit; exact figure $1.2072). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02125331)

Source record
DIN 02125331: Hydromorph Contin Raw flags: sec3=Y Item: 280808098; group id 406; item number 0970; lccId None; manufacturer id PFP Source form: CR Cap; strength: 6mg Recorded listing: General benefit Source prices (unrounded): $1.2072; ministry $1.2072 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02125331 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18558
Shortage status: resolved shortage (ended July 29, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02125331
Shortage record checked October 6, 2026

Apo-Hydromorphone · DIN 02364158 · 8 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Hydromorphone · DIN 02364158 Manufacturer: Apotex Inc.; listing date 2012-06-26 Health Canada: Marketed since 2012-12-18 · brand APO-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 8 MG · company Apotex inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Hydromorphone: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3528). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364158)

Source record
DIN 02364158: Apo-Hydromorphone Raw flags: sec3=Y Item: 280808020; group id 406; item number 0979; lccId None; manufacturer id APX Source form: Tab; strength: 8mg Recorded listing: General benefit Source prices (unrounded): $0.3528; ministry $0.3528 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364158 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84908
Interchangeable products
Dilaudid · DIN 00786543 · $0.3528 PMS-HYDROmorphone · DIN 00885428 · $0.3528 Teva-Hydromorphone · DIN 02319446 · $0.3528
Shortage status: resolved shortage (ended October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364158
Shortage record checked October 6, 2026

Dilaudid · DIN 00786543 · 8 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Dilaudid · DIN 00786543 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 2008-12-29 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 8 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00786543)

Source record
DIN 00786543: Dilaudid Raw flags: sec3=Y Item: 280808020; group id 406; item number 0979; lccId None; manufacturer id PFP Source form: Tab; strength: 8mg Recorded listing: General benefit Source prices (unrounded): $0.3892; ministry $0.3528 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00786543 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9509
Interchangeable products
Apo-Hydromorphone · DIN 02364158 · $0.3528 PMS-HYDROmorphone · DIN 00885428 · $0.3528 Teva-Hydromorphone · DIN 02319446 · $0.3528
Shortage status: resolved shortage (ended January 8, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00786543
Shortage record checked October 6, 2026

PMS-HYDROmorphone · DIN 00885428 · 8 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-HYDROmorphone · DIN 00885428 Manufacturer: Pharmascience Inc.; listing date 2001-10-11 Health Canada: Marketed since 1991-12-31 · brand PMS-HYDROMORPHONE TAB 8MG · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 8 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-HYDROmorphone: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3528). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00885428)

Source record
DIN 00885428: PMS-HYDROmorphone Raw flags: sec3=Y Item: 280808020; group id 406; item number 0979; lccId None; manufacturer id PMS Source form: Tab; strength: 8mg Recorded listing: General benefit Source prices (unrounded): $0.3528; ministry $0.3528 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00885428 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11363
Interchangeable products
Apo-Hydromorphone · DIN 02364158 · $0.3528 Dilaudid · DIN 00786543 · $0.3528 Teva-Hydromorphone · DIN 02319446 · $0.3528
Shortage status: resolved shortage (ended July 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00885428
Shortage record checked October 6, 2026

Hydromorph Contin · DIN 02359510 · 9 mg · CR capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Hydromorph Contin · DIN 02359510 Manufacturer: Purdue Pharma; listing date 2012-01-19 Health Canada: Marketed since 2011-04-14 · brand HYDROMORPH CONTIN · ATC N02AA03 HYDROMORPHONE · form Capsule (sustained-release) · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 9 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Hydromorph Contin: Formulary list price $1.59 per unit (the source does not state the unit; exact figure $1.5928). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02359510)

Source record
DIN 02359510: Hydromorph Contin Raw flags: sec3=Y Item: 280808307; group id 406; item number 0968; lccId None; manufacturer id PFP Source form: CR Cap; strength: 9mg Recorded listing: General benefit Source prices (unrounded): $1.5928; ministry $1.5928 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02359510 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84453
Shortage status: resolved shortage (ended August 12, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02359510
Shortage record checked October 6, 2026

Hydromorphone HP-10 · DIN 02145928 · 10 mg/mL · injection solution-1mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Hydromorphone HP-10 · DIN 02145928 Manufacturer: Sandoz Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 2005-08-26 · brand HYDROMORPHONE HP 10 · ATC N02AA03 HYDROMORPHONE · form Solution · route Intramuscular, Subcutaneous, Intravenous · ingredients HYDROMORPHONE HYDROCHLORIDE 10 MG/ML · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Hydromorphone HP-10: Formulary list price $4.35 per unit (the source does not state the unit; exact figure $4.3460). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02145928)

Source record
DIN 02145928: Hydromorphone HP-10 Raw flags: sec3=Y Item: 280808015; group id 406; item number 0974; lccId None; manufacturer id SDZ Source form: Inj Sol-1mL Pk; strength: 10mg/mL Recorded listing: General benefit Source prices (unrounded): $4.3460; ministry $4.3460 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02145928 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18323
Interchangeable products
Dilaudid-HP · DIN 00622133 · not recorded
Shortage status: resolved shortage (ended August 14, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02145928
Shortage record checked October 6, 2026

Hydromorph Contin · DIN 02125366 · 12 mg · CR capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Hydromorph Contin · DIN 02125366 Manufacturer: Purdue Pharma; listing date 1998-12-31 Health Canada: Marketed since 1996-12-31 · brand HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 12MG · ATC N02AA03 HYDROMORPHONE · form Capsule (sustained-release) · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 12 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Hydromorph Contin: Formulary list price $2.10 per unit (the source does not state the unit; exact figure $2.0990). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02125366)

Source record
DIN 02125366: Hydromorph Contin Raw flags: sec3=Y Item: 280808099; group id 406; item number 0971; lccId None; manufacturer id PFP Source form: CR Cap; strength: 12mg Recorded listing: General benefit Source prices (unrounded): $2.0990; ministry $2.0990 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02125366 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20171
Shortage status: resolved shortage (ended June 9, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02125366
Shortage record checked October 6, 2026

Hydromorph Contin · DIN 02243562 · 18 mg · CR capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Hydromorph Contin · DIN 02243562 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 2001-07-03 · brand HYDROMORPH CONTIN-CONTROLLED RELEASE CAP - 18MG · ATC N02AA03 HYDROMORPHONE · form Capsule (sustained-release) · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 18 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Hydromorph Contin: Formulary list price $3.03 per unit (the source does not state the unit; exact figure $3.0285). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243562)

Source record
DIN 02243562: Hydromorph Contin Raw flags: sec3=Y Item: 280808123; group id 406; item number 0972; lccId None; manufacturer id PFP Source form: CR Cap; strength: 18mg Recorded listing: General benefit Source prices (unrounded): $3.0285; ministry $3.0285 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243562 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67480
Shortage status: resolved shortage (ended September 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243562
Shortage record checked October 6, 2026

Teva-Hydromorphone · DIN 02319403 · 1 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2021 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Hydromorphone · DIN 02319403 Manufacturer: Teva Canada Limited; listing date 2012-06-26 Health Canada: Cancelled post market since 2021-07-30 · brand TEVA-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Hydromorphone: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0959). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02319403)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02319403). DIN 02319403: Teva-Hydromorphone Raw flags: dinStatus=E, sec3=Y Item: 280808017; group id 406; item number 0976; lccId None; manufacturer id TEV Source form: Tab; strength: 1mg Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $0.0959; ministry $0.0959 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02319403 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80489
Interchangeable products
Apo-Hydromorphone · DIN 02364115 · $0.0959 Dilaudid · DIN 00705438 · $0.0959 PMS-HYDROmorphone · DIN 00885444 · $0.0959
Shortage status: discontinued (August 31, 2018, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319403
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2021 — choose a marketed DIN from the same-category list.

Dilaudid · DIN 00786535 · 1 mg/mL · Oral Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-23 — choose a marketed DIN from the same-category list.Discontinued January 23, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-23 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2018-01-23 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; the ministry's EAP drug list names this generic but not this DIN: confirm the product before an EAP request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Dilaudid · DIN 00786535 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-01-23 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Liquid · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG/ML · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Dilaudid: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00786535)

Source record
DIN 00786535: Dilaudid Raw flags: notABenefit=Y, sec3=Y Item: 280808013; group id 406; item number 0975; lccId None; manufacturer id PFP Source form: Oral Sol; strength: 1mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00786535 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10173
Interchangeable products
PMS-HYDROmorphone · DIN 01916386 · $0.0931
Shortage status: discontinued (March 1, 2018, reported by PURDUE PHARMA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00786535
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 23, 2018 — choose a marketed DIN from the same-category list.

Dilaudid · DIN 00627100 · 2 mg/mL · injection solution-1mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-12-05 — choose a marketed DIN from the same-category list.Discontinued December 5, 2023 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-12-05 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2023-12-05 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; the ministry's EAP drug list names this generic but not this DIN: confirm the product before an EAP request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Dilaudid · DIN 00627100 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2023-12-05 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Liquid · route Intramuscular, Intravenous, Subcutaneous · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG/ML · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Dilaudid: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00627100)

Source record
DIN 00627100: Dilaudid Raw flags: notABenefit=Y, sec3=Y Item: 280808014; group id 406; item number 0973; lccId None; manufacturer id PFP Source form: Inj Sol-1mL Pk; strength: 2mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00627100 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5937
Interchangeable products
Hydromorphone · DIN 02145901 · $1.7830
Shortage status: resolved shortage (ended December 31, 2017); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00627100
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 5, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N02A, N02AA): coverage varies; not interchangeable

  • Morphine (M-Eslon): general benefit, not a benefit
  • Acetylsalicylic acid + butalbital + caffeine + codeine (Fiorinal C1/4): not a benefit
  • Oxycodone (Supeudol): not a benefit
  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, not a benefit

4 more in the class list below

Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

TRAMADOL HCL & ACETAMINOPHEN

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE · General benefit (2), Listed, not a benefit (2) INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. PM: https://pdf.hres.ca/dpd_pm/00065848.PDF; date July 15, 2014; DIN 00653241; fetched 2026-09-10 Product monograph BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CELECOXIB · Limited Use, codes 316, 317 1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. PM: https://pdf.hres.ca/dpd_pm/00080998.PDF; date 2025-07-09; DIN 02239941; fetched 2026-09-10 Product monograph CODEINE SULFATE TRIHYDRATE & MONOHYDRATE · Limited Use, codes 201 1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. PM: https://pdf.hres.ca/dpd_pm/00078791.PDF; date 2025-03-04; DIN 02163748; fetched 2026-09-10 Product monograph OXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. Therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, and titrated slowly, reflecting the greater frequency of decreased hepatic, renal or cardiac function, concomitant disease or other drug therapy (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00072218.PDF PM date: August 29, 2023 Source product: DILAUDID; DIN 00125083; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Dilaudid · DIN 00705438 Shortage status: active shortage (reported 2026-09-29, estimated to end 2026-10-12, last updated 2026-09-30); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00705438

Check this DIN again

Dilaudid · DIN 00125083 Shortage status: active shortage (reported 2026-08-10, estimated to end 2026-10-12, last updated 2026-09-30); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00125083

Check this DIN again

Teva-Hydromorphone · DIN 02319403 Shortage status: discontinued (2018-08-31, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319403

Check this DIN again

Dilaudid · DIN 00786535 Shortage status: discontinued (2018-03-01, reported by PURDUE PHARMA); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00786535

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Dilaudid: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026